CervoMed's neflamapimod gets UK Innovation Passport for Lewy body dementia

CervoMed Inc. (NASDAQ: CRVO) said on August 4, 2026 that its drug candidate neflamapimod has been granted an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway for its development in dementia with Lewy bodies.¹

The company described the ILAP program as one meant to speed up time to market and help new medicines reach UK patients faster.¹ Through the Innovation Passport, CervoMed gains coordinated access to a shared platform involving the MHRA, the NHS, and health technology assessment bodies including NICE, the Scottish Medicines Consortium, and the All Wales Therapeutics and Toxicology Centre, along with priority support for clinical trials and NHS engagement.¹

Neflamapimod is an oral small molecule that CervoMed describes as working by crossing the blood-brain barrier and selectively inhibiting the alpha isoform of p38 MAP kinase, which is tied to neuroinflammation and synaptic dysfunction.¹ The company said data across more than 800 trial participants in Phase 1 and Phase 2 studies showed the drug was tolerated without major issues and pointed to repeated signs of benefit, citing improvements in dementia severity and functional mobility in the 91-patient Phase 2a AscenD-LB trial.¹ The 159-patient Phase 2b RewinD-LB trial, run over 16 weeks with a 32-week extension, showed improvements in both cognitive and functional measures along with favorable trends on neurodegeneration biomarkers.¹

CervoMed said it has reached agreement with regulators, including the FDA, on a possible path to registration for neflamapimod in DLB, and is now working to find a partner to fund and run a Phase 3 trial.¹ The company also said it finished enrollment in a Phase 2a trial of neflamapimod for a frontotemporal disorder subtype called nfvPPA, with interim biomarker data expected in early fourth quarter 2026, and plans to dose the first patient in the EXPERTS-ALS Phase 2a trial in the fourth quarter of 2026.¹